Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Bionova Capital is a healthcare-focused venture capital firm based in Lisbon, Portugal, founded in 2015. The firm has transitioned to Biovance Capital Partners in 2024 after successfully raising Biovance Capital Fund I. Bionova Capital has a portfolio of two companies and has achieved two profitable exits.
Bionova Capital invests in early-stage biotech companies across Europe, with a focus on innovative life science startups. The firm has ceased making new investments as of 2024 and is concentrating on managing its existing portfolio, which includes notable investments like CellmAbs and Delox.
Notable companies in Bionova Capital's portfolio include CellmAbs, which was acquired by BioNTech, and Delox, which secured €750,000 in funding for its growth strategy.
Submit your pitch through their form at bionovacapital.com.
As of 2024: Bionova Capital has transitioned its team to Biovance Capital Partners following the successful raise of Biovance Capital Fund I.
Bionova Capital focuses on early-stage biotech companies in Europe, emphasizing innovative life science startups. As of 2024, the firm is managing its existing investments rather than pursuing new opportunities.
While specific details on leading rounds are not provided, Bionova Capital has actively invested in its portfolio companies, indicating a hands-on approach.
As of 2024, Bionova Capital has transitioned to Biovance Capital Partners and is focused on managing its existing portfolio rather than making new investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.